These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32611383)

  • 1. Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification.
    Sun X; Li L; Lyu N; Mu L; Lai J; Zhao M
    Cancer Imaging; 2020 Jul; 20(1):42. PubMed ID: 32611383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation.
    Liu W; Zheng Y; Zou R; Shen J; He W; Yang Z; Zhang Y; Li B; Yuan Y
    BMC Cancer; 2018 Nov; 18(1):1186. PubMed ID: 30497418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial.
    Peng ZW; Zhang YJ; Liang HH; Lin XJ; Guo RP; Chen MS
    Radiology; 2012 Feb; 262(2):689-700. PubMed ID: 22157201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography follow-up for the detection of hepatocellular carcinoma recurrence after initial radiofrequency ablation: a single-center experience.
    Mikami S; Tateishi R; Akahane M; Asaoka Y; Kondo Y; Goto T; Shiina S; Yoshida H; Koike K
    J Vasc Interv Radiol; 2012 Oct; 23(10):1269-75. PubMed ID: 22999746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance.
    Kang TW; Lim HK; Lee MW; Kim YS; Rhim H; Lee WJ; Gwak GY; Paik YH; Lim HY; Kim MJ
    Radiology; 2015 Jul; 276(1):274-85. PubMed ID: 25734550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis.
    Hsu CY; Liu PH; Lee YH; Hsia CY; Huang YH; Chiou YY; Tsai YJ; Nagaria TS; Huo TI
    Ann Surg Oncol; 2015 Apr; 22(4):1324-31. PubMed ID: 25326394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
    Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
    Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.
    Xu XF; Xing H; Han J; Li ZL; Lau WY; Zhou YH; Gu WM; Wang H; Chen TH; Zeng YY; Li C; Wu MC; Shen F; Yang T
    JAMA Surg; 2019 Mar; 154(3):209-217. PubMed ID: 30422241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases.
    Fukuhara T; Aikata H; Hyogo H; Honda Y; Morio K; Morio R; Hatooka M; Kobayashi T; Naeshiro N; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Chayama K
    Eur J Radiol; 2015 Aug; 84(8):1540-1545. PubMed ID: 25979193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma.
    Suh SW; Choi YS
    Yonsei Med J; 2017 Jul; 58(4):737-742. PubMed ID: 28540985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
    World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification.
    Tsilimigras DI; Bagante F; Sahara K; Moris D; Hyer JM; Wu L; Ratti F; Marques HP; Soubrane O; Paredes AZ; Lam V; Poultsides GA; Popescu I; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Aldrighetti L; Endo I; Pawlik TM
    Ann Surg Oncol; 2019 Oct; 26(11):3693-3700. PubMed ID: 31267302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation.
    Facciorusso A; Del Prete V; Antonino M; Crucinio N; Neve V; Di Leo A; Carr BI; Barone M
    Dig Liver Dis; 2014 Nov; 46(11):1014-9. PubMed ID: 25085684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.